Results 241 to 250 of about 95,952 (294)

Disposition and Absolute Bioavailability of Furosemide in Healthy Males

Journal of Pharmaceutical Sciences, 1982
Furosemide (40 mg) was administered to 18 healthy adult males as an intravenous dose, an oral solution, and in tablet form. The pharmacokinetics of intravenous furosemide were studied, determining a total body clearance rate of 117.6 +/- 41.3 ml/min and a harmonic mean half-life of 78 min.
E S, Waller, S F, Hamilton, J W, Massarella, M A, Sharanevych, R V, Smith, G J, Yakatan, J T, Doluisio   +6 more
exaly   +3 more sources

Absolute bioavailability of letrozole in healthy postmenopausal women

Biopharmaceutics & Drug Disposition, 1997
Letrozole is a new non-steroidal inhibitor of the aromatase enzyme system. It is currently under development for the treatment of postmenopausal women with advanced breast cancer. Absolute bioavailability of letrozole when given orally as one 2.5 mg film-coated tablet in comparison to the same dose given intravenously as a bolus injection was studied ...
A, Sioufi, N, Gauducheau, V, Pineau, F, Marfil, A, Jaouen, J M, Cardot, J, Godbillon, C, Czendlik, H, Howald, C, Pfister, F, Vreeland   +10 more
exaly   +3 more sources

Absolute bioavailability of moxonidine

European Journal of Drug Metabolism and Pharmacokinetics, 1991
In a randomized 2-way cross-over study with eighteen healthy male volunteers, two moxonidine preparations (tablets, treatment A vs. intravenous solution, treatment B) were tested to investigate absolute bioavailability and pharmacokinetics of moxonidine.
R, Theodor, H J, Weimann, W, Weber, K, Michaelis   +3 more
openaire   +2 more sources

Absolute Bioavailability of Tasimelteon

American Journal of Therapeutics, 2015
Tasimelteon is a novel dual melatonin receptor agonist and is the first treatment approved by the US Food and Drug Administration for Non-24-Hour Sleep-Wake Disorder. This study was conducted to assess the absolute bioavailability of tasimelteon and to further assess the single-dose pharmacokinetics, safety, and tolerability of oral and intravenous (IV)
Rosarelis, Torres, Marlene A, Dressman, William G, Kramer, Paolo, Baroldi   +3 more
openaire   +2 more sources

Absolute bioavailability of moxifloxacin

Clinical Therapeutics, 1999
Moxifloxacin (BAY 12-8039) is an investigational 8-methoxy-fluoroquinolone with broad-spectrum gram-positive and gram-negative activity. To determine the absolute bioavailability of moxifloxacin, this open-label, randomized, crossover study compared the pharmacokinetic characteristics of a single 100-mg dose administered either orally or intravenously ...
C, Ballow, J, Lettieri, V, Agarwal, P, Liu, H, Stass, J T, Sullivan   +5 more
openaire   +2 more sources

Absolute quinidine bioavailability

Clinical Pharmacology & Therapeutics, 1976
The absolute bioamilability of quinidine was studied in II hospitalized patients. A 400‐mg dose of quinidine gluconate was administered to each patient In intravenous infusion and as an oral solution. Drug treatments were separated by a 72‐hr period. In 8 patients.
C T, Ueda, B J, Williamson, B S, Dzindzio   +2 more
openaire   +2 more sources

Pharmacokinetics and absolute bioavailability of lansoprazole

European Journal of Clinical Pharmacology, 1996
In a crossover study 12 healthy volunteers received lansoprazole 15 mg or 30 mg orally, or 15 mg intravenously in randomized order as a single dose. Blood samples were taken and plasma levels of lansoprazole were determined using an HPLC method. The volunteers were phenotyped for the debrisoquine/sparteine and mephenytoin polymorphisms.The total ...
J, Gerloff, A, Mignot, H, Barth, K, Heintze   +3 more
openaire   +2 more sources

Absolute Bioavailability of Himantane in Rabbits

Bulletin of Experimental Biology and Medicine, 2012
Pharmacokinetic parameters of himantane and its metabolites in the blood plasma of rabbits were compared after single administration of himantane solution in a dose of 25 mg intravenously and 100 mg orally. It was established that the original substance is characterized by low absolute bioavailability (7.95%).
E A, Litvin, D V, Bastrygin, G B, Kolyvanov, K V, Alekseev, V P, Zherdev   +4 more
openaire   +2 more sources

The Absolute Bioavailability of Oral Melatonin

The Journal of Clinical Pharmacology, 2000
The absolute bioavailability of oral melatonin tablets was studied in 12 normal healthy volunteers. Subjects were administered, in a randomized crossover fashion, melatonin 2 mg intravenously and 2 and 4 mg orally. Blood was sampled over approximately eight (estimated) half‐lives.
R L, DeMuro, A N, Nafziger, D E, Blask, A M, Menhinick, J S, Bertino   +4 more
openaire   +2 more sources

Zaleplon pharmacokinetics and absolute bioavailability

Biopharmaceutics & Drug Disposition, 1999
The pharmacokinetics and absolute oral bioavailability of zaleplon were assessed to evaluate the extent of presystemic metabolism of this new nonbenzodiazepine hypnotic agent. A partially randomized, single-dose, four-period crossover study was conducted in 23 healthy subjects.
A S, Rosen, P, Fournié, M, Darwish, P, Danjou, S M, Troy   +4 more
openaire   +2 more sources